Fig. 1From: Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trialSPIRIT study design. Patients aged 12 years and older with inadequately controlled moderate-to-severe asthma receiving Global Initiative for Asthma (GINA) Steps 3, 4 and 5 standard of care asthma therapy were randomly assigned (3:3:1) to receive either fevipiprant 150 mg, fevipiprant 450 mg, or placebo once dailyBack to article page